ATE309328T1 - Somatische zellen mit funktionsunfähigem prp gen und verwendungsverfahren - Google Patents

Somatische zellen mit funktionsunfähigem prp gen und verwendungsverfahren

Info

Publication number
ATE309328T1
ATE309328T1 AT99968879T AT99968879T ATE309328T1 AT E309328 T1 ATE309328 T1 AT E309328T1 AT 99968879 T AT99968879 T AT 99968879T AT 99968879 T AT99968879 T AT 99968879T AT E309328 T1 ATE309328 T1 AT E309328T1
Authority
AT
Austria
Prior art keywords
prp gene
cells
somatic cells
defunctional
gene
Prior art date
Application number
AT99968879T
Other languages
English (en)
Inventor
Stanley B Pruniser
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22822825&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE309328(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of ATE309328T1 publication Critical patent/ATE309328T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT99968879T 1998-12-22 1999-12-13 Somatische zellen mit funktionsunfähigem prp gen und verwendungsverfahren ATE309328T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22026598A 1998-12-22 1998-12-22
PCT/US1999/029503 WO2000037612A1 (en) 1998-12-22 1999-12-13 SOMATIC CELLS WITH ABLATED Prp GENE AND METHODS OF USE

Publications (1)

Publication Number Publication Date
ATE309328T1 true ATE309328T1 (de) 2005-11-15

Family

ID=22822825

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99968879T ATE309328T1 (de) 1998-12-22 1999-12-13 Somatische zellen mit funktionsunfähigem prp gen und verwendungsverfahren

Country Status (12)

Country Link
EP (1) EP1141245B1 (de)
JP (1) JP2002533070A (de)
KR (1) KR20020013484A (de)
AT (1) ATE309328T1 (de)
AU (1) AU767893B2 (de)
BR (1) BR9916475A (de)
CA (1) CA2356244A1 (de)
DE (1) DE69928284T2 (de)
ES (1) ES2253000T3 (de)
IL (1) IL143705A0 (de)
NZ (1) NZ512309A (de)
WO (1) WO2000037612A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2009123458A (ru) * 2006-11-20 2010-12-27 Октагене Гмбх (De) Генетическая абляция клеток, несущих ген prp, с использованием стратегии направленной промоторной ловушки для получения бессывороточных рекомбинантных белков в качестве терапевтических препаратов

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0613495B1 (de) * 1991-11-14 2005-02-02 WEISSMANN, Charles Transgene nicht-menschliche tiere ohne prionprotein

Also Published As

Publication number Publication date
WO2000037612A1 (en) 2000-06-29
ES2253000T3 (es) 2006-05-16
CA2356244A1 (en) 2000-06-29
NZ512309A (en) 2003-05-30
EP1141245A1 (de) 2001-10-10
BR9916475A (pt) 2001-12-04
EP1141245B1 (de) 2005-11-09
AU2708300A (en) 2000-07-12
DE69928284D1 (de) 2005-12-15
DE69928284T2 (de) 2006-08-10
JP2002533070A (ja) 2002-10-08
IL143705A0 (en) 2002-04-21
KR20020013484A (ko) 2002-02-20
AU767893B2 (en) 2003-11-27

Similar Documents

Publication Publication Date Title
Jiang et al. Deletion and replacement of long genomic sequences using prime editing
Rathke et al. Transition from a nucleosome-based to a protamine-based chromatin configuration during spermiogenesis in Drosophila
Morocz et al. DNA-dependent protease activity of human Spartan facilitates replication of DNA–protein crosslink-containing DNA
Li et al. Optimization of genome engineering approaches with the CRISPR/Cas9 system
Beagan et al. Drosophila DNA polymerase theta utilizes both helicase-like and polymerase domains during microhomology-mediated end joining and interstrand crosslink repair
Povelones et al. Histone H1 plays a role in heterochromatin formation and VSG expression site silencing in Trypanosoma brucei
Mulholland et al. A modular open platform for systematic functional studies under physiological conditions
Sato et al. The combinational use of CRISPR/Cas9‐based gene editing and targeted toxin technology enables efficient biallelic knockout of the α‐1, 3‐galactosyltransferase gene in porcine embryonic fibroblasts
Wei et al. Efficient introgression of allelic variants by embryo-mediated editing of the bovine genome
Kornete et al. Highly efficient and versatile plasmid-based gene editing in primary T cells
ATE407138T1 (de) Verfahren zur herstellung interferierender rna- moleküle in säugetierzellen und therapeutische anwendungen solcher moleküle
van de Vrugt et al. Effective CRISPR/Cas9-mediated correction of a Fanconi anemia defect by error-prone end joining or templated repair
García-Tuñón et al. Splice donor site sgRNAs enhance CRISPR/Cas9-mediated knockout efficiency
CN112048497B (zh) 一种新型的单碱基编辑技术及其应用
Paulis et al. A pre-screening FISH-based method to detect CRISPR/Cas9 off-targets in mouse embryonic stem cells
Vannocci et al. A new cellular model to follow Friedreich's ataxia development in a time-resolved way
Wang et al. Efficient targeted integration into the bovine Rosa26 locus using TALENs
Mori et al. Genome structure and differential expression of two isoforms of a novel PDZ-containing myosin (MysPDZ)(Myo18A)
Chen et al. Targeted genome engineering in Caenorhabditis elegans
Uhrig et al. Disparate requirements for RAD54L in replication fork reversal
Komori et al. A CRISPR-del-based pipeline for complete gene knockout in human diploid cells
Camarasa et al. RETRACTED ARTICLE: Robust method for TALEN-edited correction of pF508del in patient-specific induced pluripotent stem cells
DE60128122D1 (de) Kernumprogrammierung bei iswi und ähnlichen chromatinremodellierenden atpasen
Dong et al. PPP4C facilitates homologous recombination DNA repair by dephosphorylating PLK1 during early embryo development
Maeder et al. 124. Therapeutic correction of an LCA-causing splice defect in the CEP290 gene by CRISPR/Cas-mediated gene editing

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties